NCT00345163View on ClinicalTrials.gov

A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)

PHASE2CompletedINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Glioblastoma
Interventions
DRUG

bevacizumab

Intravenous repeating dose

DRUG

irinotecan

Intravenous repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY